The stock of Inozyme Pharma Inc (INZY) has seen a 243.48% increase in the past week, with a 310.69% gain in the past month, and a 188.32% flourish in the past quarter. The volatility ratio for the week is 15.50%, and the volatility levels for the past 30 days are at 16.19% for INZY. The simple moving average for the last 20 days is 199.26% for INZY stock, with a simple moving average of 34.47% for the last 200 days.
Is It Worth Investing in Inozyme Pharma Inc (NASDAQ: INZY) Right Now?
Company’s 36-month beta value is 1.42.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 4 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for INZY is 43.53M, and currently, short sellers hold a 9.16% ratio of that floaft. The average trading volume of INZY on May 19, 2025 was 817.31K shares.
INZY) stock’s latest price update
Inozyme Pharma Inc (NASDAQ: INZY) has seen a rise in its stock price by 178.17 in relation to its previous close of 1.42. However, the company has experienced a 243.48% gain in its stock price over the last five trading sessions. prnewswire.com reported 2025-05-16 that NEW YORK, May 16, 2025 /PRNewswire/ — Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Inozyme Pharma, Inc. (NASDAQ: INZY ), relating to the proposed merger with BioMarin Pharmaceutical Inc. Under the terms of the agreement, BioMarin will commence a cash tender offer to acquire all of the outstanding shares of Inozyme common stock at a price of $4.00 per share.
Analysts’ Opinion of INZY
Many brokerage firms have already submitted their reports for INZY stocks, with Raymond James repeating the rating for INZY by listing it as a “Outperform.” The predicted price for INZY in the upcoming period, according to Raymond James is $26 based on the research report published on December 12, 2024 of the previous year 2024.
Stifel, on the other hand, stated in their research note that they expect to see INZY reach a price target of $16. The rating they have provided for INZY stocks is “Buy” according to the report published on September 12th, 2024.
Jefferies gave a rating of “Buy” to INZY, setting the target price at $17 in the report published on August 13th of the previous year.
INZY Trading at 257.74% from the 50-Day Moving Average
After a stumble in the market that brought INZY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.70% of loss for the given period.
Volatility was left at 16.19%, however, over the last 30 days, the volatility rate increased by 15.50%, as shares surge +329.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +221.14% upper at present.
During the last 5 trading sessions, INZY rose by +243.48%, which changed the moving average for the period of 200-days by -31.18% in comparison to the 20-day moving average, which settled at $1.32. In addition, Inozyme Pharma Inc saw 42.60% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INZY starting from Treco Douglas A, who sale 8,819 shares at the price of $0.89 back on Apr 02 ’25. After this action, Treco Douglas A now owns 41,046 shares of Inozyme Pharma Inc, valued at $7,849 using the latest closing price.
Stock Fundamentals for INZY
The total capital return value is set at -2.05. Equity return is now at value -141.69, with -78.44 for asset returns.
Based on Inozyme Pharma Inc (INZY), the company’s capital structure generated 0.45 points at debt to capital in total, while cash flow to debt ratio is standing at -3.66. The debt to equity ratio resting at 0.83. The interest coverage ratio of the stock is -37.98.
Currently, EBITDA for the company is -104.03 million with net debt to EBITDA at -0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.19.
Conclusion
In a nutshell, Inozyme Pharma Inc (INZY) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
